Case Summary (G.R. No. 182358)
Factual Background
At the instance of the Department of Health, AO 27 established accreditation procedures for government suppliers of pharmaceutical products. AO 10 amended AO 27 to shorten the accreditation period and authorized recall, suspension, or revocation of accreditation by the DOH Accreditation Committee. Memorandum No. 171-C set out sanctions for accredited suppliers against whom adverse findings were made. On October 27, 2000, Undersecretary Ma. Margarita M. Galon convened representatives of 24 accredited suppliers, including PPI, and distributed the Report on Violative Products issued by the Bureau of Food and Drugs, which identified several PPI products as unfit for human consumption.
PPI’s Response and Suspension
Undersecretary Galon directed the suppliers to submit explanations within ten days. PPI did not meet the deadline and instead sent a belated letter dated November 13, 2000 stating that it had referred the matter to counsel and that its lawyers would prepare a reply. The letter did not state when a reply would be furnished nor did it seek an extension. In response, Undersecretary Galon issued a letter dated November 23, 2000 suspending PPI’s accreditation for two years pursuant to AO 10 and Memorandum No. 171-C.
Complaint and Prayer for Relief
On December 28, 2000, PPI filed Civil Case No. 68200 in the Regional Trial Court of Pasig City seeking to declare null and void AO 10, Memorandum No. 171-C, Undersecretary Galon’s suspension order, and later AO 14. PPI alleged that Section 26(d) of RA 3720, as amended by EO 175, vested the BFAD Director with exclusive authority to give notice and hear persons whose products are found adulterated or misbranded, and that the DOH issuances usurped that power. PPI also prayed for moral and exemplary damages, attorneys’ fees, costs, and injunctive relief.
Trial Court Proceedings
The DOH and the individual petitioners answered and moved for dismissal, asserting that the action was effectively a suit against the State and invoking state immunity. The trial court granted a limited temporary restraining order but later dismissed Civil Case No. 68200 on the ground that it constituted a suit against the State and was therefore barred by the doctrine of non-suability.
Court of Appeals Disposition
On appeal, the Court of Appeals reversed and set aside the trial court dismissal and remanded the case for further proceedings. The CA reasoned that the complaint sufficiently alleged acts beyond the scope of official authority and that petitioners’ motion to dismiss amounted to a hypothetical admission of those allegations, including that petitioners were sued in their personal capacities. The CA concluded that the question whether the suit was against the State should be resolved at trial on the merits.
Issue Presented to the Supreme Court
The sole issue posed to the Supreme Court was whether Civil Case No. 68200 should be dismissed for being a suit against the State.
Petitioners’ Principal Contentions
Petitioners argued that the complaint sought damages against the DOH, thereby imposing a financial liability that would require appropriation by the State and thus amounted to a suit against the State. They maintained that they acted within the scope of their official authority in issuing and implementing the challenged issuances and thus could not be held individually liable.
Respondent’s Principal Contentions
PPI maintained that the complaint alleged acts beyond the scope of official authority and that it sued the petitioners in their private and personal capacities. PPI urged that state immunity did not bar the action because the officials acted ultra vires or otherwise outside their jurisdiction.
Legal Doctrine on Non-Suability Applied
The Court recapitulated the doctrine of non-suability that the State may not be sued without its consent and that such consent may be express by statute or implied by contract or by the State initiating litigation. The Court emphasized that statutory waivers of immunity are construed in strictissimi juris because waiver is in derogation of sovereignty. The Court reiterated that an unincorporated government agency performing governmental functions enjoys immunity from suit, whereas immunity may not extend to agencies acting in proprietary capacities.
Application of Doctrine to the DOH and Officials
The Court found that the DOH, as an unincorporated agency performing sovereign and governmental functions, could validly invoke state immunity because it did not consent to be sued. The complaint sought moral and exemplary damages, attorneys’ fees, and costs against the DOH and the named officials jointly and severally, which would impose a financial charge requiring appropriation from the national treasury if PPI prevailed. The Court held that such a result falls squarely within the protection of the doctrine of non-suability.
Acts Were Within Official Functions; No Bad Faith Shown
The Court concluded that the acts imputed to Secretaries Romualdez and Dayrit and Undersecretary Galon were performed in the exercise of their official functions. The suspension order flowed from a directive emanating from the DOH structure and the BFAD, which is an office under the Health Secretary. Undersecretary Galon was authorized to supervise offices under the DOH, including the BFAD. The record contained no showing of bad faith or that the officials acted ultra vires. The suspension followed PPI’s failure to co
...continue reading
Case Syllabus (G.R. No. 182358)
Parties and Procedural Posture
- THE SECRETARY OF HEALTH and MA. MARGARITA M. GALON filed a Petition for Review on Certiorari assailing the Court of Appeals' October 25, 2007 Decision in CA-G.R. CV No. 85670 and its March 31, 2008 Resolution denying reconsideration.
- PHIL PHARMAWEALTH, INC. was the plaintiff in Civil Case No. 68200 filed before the Regional Trial Court of Pasig City seeking nullification of certain DOH issuances, damages, and injunctive relief.
- The Regional Trial Court dismissed Civil Case No. 68200 on the ground that it constituted a suit against the State, and the Court of Appeals reversed and remanded for further proceedings.
- The Supreme Court granted the Petition for Review on Certiorari and rendered the dispositive judgment in this case.
Key Factual Allegations
- The Department of Health issued Administrative Order No. 27, series of 1998 establishing accreditation guidelines for government suppliers of pharmaceutical products.
- Administrative Order No. 10, series of 2000 amended AO 27 to reduce the accreditation period to two years and authorize recall, suspension, or revocation by the DOH Accreditation Committee.
- Administrative Order No. 66, series of 2000 further amended AO 10 to require deliberation, hearing, and notice by the Accreditation Committee prior to recall, suspension, or revocation.
- The DOH issued Memorandum No. 171-C prescribing categories of sanctions for accredited suppliers with adverse findings and Undersecretary Ma. Margarita M. Galon issued Memorandum No. 209, series of 2000 inviting representatives of accredited suppliers to a meeting on October 27, 2000.
- At the October 27, 2000 meeting, attendees received the Report on Violative Products from the Bureau of Food and Drugs (BFAD) which identified several PHIL PHARMAWEALTH, INC. products as unfit for human consumption and were directed to submit explanations within ten days.
- PHIL PHARMAWEALTH, INC. sent a belated letter dated November 13, 2000 indicating referral of the Report to its lawyers and failing to state when a reply would be submitted.
- Undersecretary Galon suspended PHIL PHARMAWEALTH, INC.'s accreditation effective November 23, 2000, citing AO 10 and Memorandum No. 171-C.
- PHIL PHARMAWEALTH, INC. filed suit on December 28, 2000 praying for nullification of the issuances, temporary and permanent injunctive relief, and moral damages of P5 million, exemplary damages of P1 million, attorneys' fees of P1 million, and costs of suit.
Statutory Framework
- Republic Act No. 3720 (Food, Drug, and Cosmetic Act) as amended by Executive Order No. 175 is the primary statutory scheme governing BFAD functions and the administrative hearing requirement in Section 26(d).
- Administrative Order No. 27, series of 1998, Administrative Order No. 10, series of 2000, Administrative Order No. 66, series of 2000, and Memorandum No. 171-C are the DOH issuances challenged by PHIL PHARMAWEALTH, INC.
- The Administrative Code provision cited to establish supervisory authority over BFAD was Section 12, Chapter 3, Title IX, Book IV, Administrative Code of 1987.
- The BFAD was identified as an office under the Office of the Health Secretary pursuant to Section 4 of RA 3720.
Trial Court Proceedings
- The trial court initially granted a limited temporary restraining order covering products not included in the BFAD list of violative products.
- Petitioners moved to dismiss Civil Case No. 68200 on the grounds that it constituted a suit against the State, lacked proper verifica